| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Autobiography |
| Article Title |
Metastatic type 1 gastric carcinoid: A real threat or just a myth?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Simona Grozinsky-Glasberg, Dimitrios Thomas, Jonathan R Strosberg, Ulrich-Frank Pape, Stephan Felder, Apostolos V Tsolakis, Krystallenia I Alexandraki, Merav Fraenkel, Leonard Saiegh, Petachia Reissman, Gregory Kaltsas and David J Gross |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Dr. Simona Grozinsky-Glasberg, MD, Neuroendocrine Tumor Unit, Endocrinology and Metabolism Service, Department of Medicine, Hadassah-Hebrew University Medical Center, PO Box 12000, 91120 Jerusalem, Israel. simonag@hadassah.org.il |
| Key Words |
Metastatic gastric carcinoids; Gastrin; Chromogranin A; Somatostatin analogues; Stomach neuroendocrine tumor |
| Core Tip |
Metastatic gastric carcinoid type 1 (GCA1) are extremely rare and there is no data regarding their natural history, treatment and prognosis. Based on our study, metastatic GCA1 carries a good overall prognosis. Metastatic spread appears to be related to a tumor size of ≥ 1 cm, an elevated Ki-67 index, and to high serum gastrin levels. Endoscopic surveillance is extremely important for follow-up. Surgical resection should be performed only in patients in whom total tumor excision is expected. Although still controversial, somatostatin analogues could be considered as first line treatment to lower the elevated gastrin levels and suppress enterochromaffin like cell hyperplasia. |
| Publish Date |
2013-12-18 10:00 |
| Citation |
Grozinsky-Glasberg S, Thomas D, Strosberg JR, Pape UF, Felder S, Tsolakis AV, Alexandraki KI, Fraenkel M, Saiegh L, Reissman P, Kaltsas G, Gross DJ. Metastatic type 1 gastric carcinoid: A real threat or just a myth? World J Gastroenterol 2013; 19(46): 8687-8695 |
| URL |
http://www.wjgnet.com/1007-9327/full/v19/i46/8687.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v19.i46.8687 |
